CLINICAL RESEARCH: HEART RHYTHM DISORDER
Syncope Predicts the Outcome of Cardiomyopathy PatientsAnalysis of the SCD-HeFT Study
Brian Olshansky, MD, FACC*,*,
Jeanne E. Poole, MD, FACC ,
George Johnson, BSEE||,
Jill Anderson, RN||,
Anne S. Hellkamp, MS ,
Douglas Packer, MD, FACC ,
Daniel B. Mark, MD, MPH, FACC ,
Kerry L. Lee, PhD ,
Gust H. Bardy, MD, FACC|| for the SCD-HeFT Investigators
* University of Iowa, Iowa City, Iowa
University of Washington, Seattle, Washington
Mayo Clinic, Rochester, Minnesota
Duke University, Durham, North Carolina
|| Seattle Institute for Cardiac Research, Seattle, Washington.
Manuscript received August 10, 2007;
revised manuscript received October 29, 2007,
accepted November 21, 2007.
* Reprint requests and correspondence: Dr. Brian Olshansky, Professor of Medicine, University of Iowa Hospitals, 200 Hawkins Drive, Iowa City, Iowa 52242. (Email: brian-olshansky{at}uiowa.edu).
Objectives: The outcome of congestive heart failure (CHF) patients with syncope is understood incompletely.
Background: We analyzed data from patients enrolled in the SCD-HeFT (Sudden Cardiac Death Heart Failure Trial) to determine whether syncope predicted outcomes in patients with CHF.
Methods: We compared outcomes (and associated clinical characteristics) in patients with and without syncope enrolled in SCD-HeFT.
Results: In SCD-HeFT, 162 (6%) patients had syncope before randomization, 356 (14%) had syncope after randomization (similar incidence in each randomized arm), and 46 (2%) had syncope before and after randomization. A QRS duration 120 ms and absence of beta-blocker use predicted syncope during follow-up (hazard ratio [HR] 1.30 and 95% confidence interval [CI] 1.06 to 1.61, p = 0.014 and HR 1.25, 95% CI 1.01 to 1.56, p = 0.048, respectively). Syncope recurrence did not differ by randomization arm. However, in the implantable cardioverter-defibrillator (ICD) arm, syncope, before and after randomization, was associated with appropriate ICD discharges (HR 1.75, 95% CI 1.10 to 2.80, p = 0.019 and HR 2.91, 95% CI 1.89 to 4.47, p = 0.001, respectively). Post-randomization syncope predicted total and cardiovascular death (HR 1.41, 95% CI 1.13 to 1.76, p = 0.002 and HR 1.55, 95% CI 1.19 to 2.02, p = 0.001, respectively). The elevated relative risk of mortality for syncope versus nonsyncope patients did not vary significantly across treatment arms (ICD, HR 1.54, 95% CI 1.04 to 2.27; amiodarone, HR 1.33, 95% CI 0.91 to 1.93; and placebo, HR 1.39, 95% CI 0.96 to 2.02, test for difference p = 0.86).
Conclusions: For CHF patients with ICDs, syncope was associated with appropriate ICD activations. Syncope was associated with increased mortality risk in SCD-HeFT regardless of treatment arm (placebo, amiodarone, or ICD). (SCD-HeFT Trial; NCT00000609
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | CI = confidence interval | | ECG = electrocardiogram | | HR = hazard ratio | | ICD = implantable cardioverter-defibrillator | | NYHA = New York Heart Association |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A29-A30.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
D. G. Benditt and J. T. Nguyen
Syncope: therapeutic approaches.
J. Am. Coll. Cardiol.,
May 12, 2009;
53(19):
1741 - 1751.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|
|